Avemar - Cancer Medication Solutions

www.avemar.com

Product information
Review 1. - THE PRODUCT AND ITS REGISTRATION STATUS

Avemar is a mixture of molecules with a standardized composition derived from chemically modified natural materials. The main component is wheat germ, from which several different substances are extracted. These substances are then altered chemically, through the use of enzymatic and microorganism-derived processes, or by means of fermentational and bio-technological transformation, all in conformation to the quality standards set out for pharmaceutical production (GMP, ISO 9001:2000). After their concentration, the active ingredients are extracted using various physicochemical processes and then molecularly encapsulated and formulated. The result is a semi-natural, semi-synthetic substance in granular form which must be dissolved in water before being ingested. Owing to its complex nature, Avemar contains numerous additional molecules besides its main ingredient.

Composition
Avemar is a mixture of molecules with a standardized composition derived from chemically modified natural materials. Its main component is wheat germ, from which several different substances are extracted. These substances are then altered chemically, through the use of enzymatic and microorganism-derived processes, or by means of fermentational and biotechnological transformation, all in conformation to the quality standards set out for pharmaceutical production (GMP, ISO 9001:2000). After their concentration, the active ingredients are extracted using various physicochemical processes and then molecularly encapsulated and formulated. The result is a semi-natural, semi-synthetic substance in granular form which must be dissolved in water before being ingested. The product is standardized as methoxy-substituted benzoquinones (0.04%), namely 2-methoxy-benzoquinone and 2.6-dimethoxy-benzoquinone. Owing to its complex nature, Avemar contains numerous additional molecules besides its main ingredient. While these compounds are responsible for the peculiar taste of the product, their removal would weaken the product's effectiveness. As some of Avemar's active ingredients are slightly heat-sensitive, the final product must be kept at room temperature, in a refrigerator if possible.

Indications
Avemar is a medical nutriment for complementing cancer treatment during and after surgery, radiotherapy, chemotherapy and immune therapy. The continuous use of Avemar is recommended during the full course of clinical treatment and after its completion for as long as recommended by the treating physician. After surgery, the administration of Avemar can begin when the patient has been able to take food orally and without complications for at least 4 days.

Mode of action

1. Immunmodulatory effect
1. Enhancement of blastic transformation
2. Restoration of damaged immune response
2. Stimulation of apoptosis (programmed cell death): Cleavage of PARP (poly-(ADP-ribose)polymerase-) induced by caspase-3 protease (nuclear enzyme)
3. Effects on glucose/nucleic acid metabolism. Avemar decreases the glucose-uptake of tumour cells in a dose-dependent manner and inhibits the production of ribose and desoxyribose. Avemar inhibits the activity of glucose-6-phosphate dehydrogenase and transketolase (i.e. the key enzymes of ribose synthesis).
4. Exerts a selective inhibition of MHC-I (main histocompatibility-I) expression on the surface of tumour cells.
5. Enhances TNFalpha (tumor necrosis factor alpha) production, thereby inhibiting tumour angiogenesis.
6. ICAM-I: the intracellular adhesion molecule (CD 45) level is increased by Avemar.
7. Inhibition of carcinogenesis/chemo-preventive effect: Avemar is capable of inhibiting the development of rat colon tumours induced with azoxymethane
8. Stimulation of haemopoesis: regeneration of thrombopoesis and erythropoesis in cyclophosphamide-induced bone marrow impairment


Preclinical anti-cancer effects
1. In mice 3LL-HH tumour and HCR-25 human colon carcinoma xenograft: disappearance of liver metastases. In B-16 melanoma: decrease in the number of liver and lung metastatic foci. In rat nephroblastoma: simultaneous use of Avemar and vitamin C decreased the growth of the primary tumour.

2. The combined use of Avemar with cytostatics:
in mouse C-38 colorectal carcinoma: synergism between 5-fluoro-uracyl (5-FU) and Avemar. In B-16 melanoma: synergism between DTIC and Avemar.